Propanc Biopharma Reports Strong Preclinical PRP Results
MELBOURNE, Australia, August 6, 2026 Propanc Biopharma announced compelling preclinical and early translational findings for its lead investigational therapy...
Pancreatic Ductal Adenocarcinoma
Advertisement
Revolution Medicines FDA Accepts Daraxonrasib NDA for Pancreatic Cancer
Revolution Medicines, Redwood City, Calif., July 22, 2026 Revolution Medicines announced that the U.S. Food and Drug Administration (FDA)...
Revolution Medicines Advances Daraxonrasib Under EMA Review
REDWOOD CITY, Calif., July 7, 2026 Revolution Medicines has announced a major regulatory milestone as the European Medicines Agency...
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
Verastem Oncology Shows Encouraging Survival Data in RAMP 205 Pancreatic Cancer Trial
BOSTON, June 17, 2026 Verastem Oncology announced positive updated safety and efficacy findings from the Phase 1b/2a RAMP 205...
Advertisements
Verastem Oncology Doses First Patient in TARGET-D 201 Trial
BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...
Anocca Doses First Patients with KRAS-Targeted TCR-T Therapy
SÖDERTÄLJE, Sweden, June 11, 2026 Anocca AB announced the successful dosing of the first patients in its VIDAR-1 clinical...
Advertisement
